Investor Relations

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.

Press Releases
Jun 10, 2022

Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response...

Jun 4, 2022

TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses Potential for...

View all press releases >>

Events & Presentations
Thursday, June 9, 2022
11:00am - 12:00pm EDT
Thursday, May 5, 2022
4:30pm - 5:30pm EDT

View all events & presentations >>

Latest Presentation
Investor Alerts

Receive the latest alerts via email.

Sign up

Contact IR

Curis, Inc.
128 Spring Street
Building C- Suite 500

Lexington, MA 02421
Phone: 617-503-6500

Transfer Agent

250 Royall Street
Canton, MA 02021
Phone: 877-810-2248

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.